Compare Visa Inc (V) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Visa Inc vs Viatris Inc — how do they compare? Visa Inc trades at $368.99 (market cap $693.57B), while Viatris Inc trades at $16.45 (market cap $19.09B). The key difference: Visa Inc is far larger — about 36.3× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.89%). Which is the better fit depends on your goals.
| V | VTRS | |
|---|---|---|
Market Cap | $693.57B | $19.09B |
Volume | 10,431,336 | — |
Sector | Financials | Health |
52-Week High | $384.14 | $17.86 |
52-Week Low | $295.52 | $9.49 |
Enterprise Value | $704.15B | $31.21B |
Dividend Yield | 0.73% | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Visa (V) trades at $368.64, down 1.71% on the day, amid a bullish technical setup with strong support at $366 and resistance at $372. The company reported robust fundamentals with Q2 2026 earnings beating estimates, revenue growth to $40B in 2025, and a net income margin of 50.78%. Recent news highlights Visa's push into AI-driven commerce and stablecoin partnerships, signaling innovation in payments.
Outlook remains positive with an analyst consensus price target of $430.93 (17% upside), supported by high profitability and strategic initiatives. Risks include fintech competition and regulatory pressures, but institutional ownership trends and a debt-to-asset ratio of 25.26% reflect financial stability. The stock presents a long-term growth opportunity with manageable headwinds.
Viatris (VTRS) trades at $16.61, down 1.6% over the past 24 hours. The stock exhibits a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company reported a net loss of $3.51 billion in 2025 despite revenue of $14.30 billion, though recent quarters have shown earnings beats. Positive cash flow generation and a dividend payment highlight financial stability, while analyst sentiment is mixed with a majority hold rating.
The outlook for VTRS hinges on its ability to return to profitability and sustain operational improvements. Investment opportunities include strong cash flow, deleveraging progress, and pipeline developments, but risks involve persistent net losses, competitive pressures, and potential regulatory impacts from proposed generic drug tariffs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
